ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Arham Quraishi1, Isfaqul Hussain1 , Shaheen Farooq1,
Zahid Amin Kashoo1, Najeeb Ul Tarfain1, Sabia Qureshi1,
Mir Nadeem Hassan1, Mohd Altaf Bhat1, Mansoor Nabi Mir1, Syed Mudasir Ahmad2, Syed Akram Hussain3 and Zahoor Ahmad Wani4
1Division of Veterinary Microbiology and Immunology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-Kashmir, Shuhama, Srinagar, Jammu and Kashmir, India.
2Division of Animal Biotechnology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-Kashmir, Shuhama, Srinagar, Jammu and Kashmir, India.
3Division of Veterinary Public Health, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-Kashmir, Shuhama, Srinagar, Jammu and Kashmir, India.
4Division of Veterinary Parasitology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-Kashmir, Shuhama, Srinagar, Jammu and Kashmir, India.
Article Number: 9741 | © The Author(s). 2025
J Pure Appl Microbiol. 2025;19(1):255-262. https://doi.org/10.22207/JPAM.19.1.16
Received: 18 July 2024 | Accepted: 20 December 2024 | Published online: 07 February 2025
Issue online: March 2025
Abstract

Virulent footrot represents as a significant contagious ailment affecting sheep, with Dichelobacter nodosus being the primary agent responsible for transmitting the disease. Vaccinations and various management practices are utilized to control the disease. In this study, we cultured D. nodosus in broth culture under reducing conditions and formulated a vaccine using Montanide oil as adjuvant. The efficacy of the vaccine was assessed in sheep to determine its ability to elicit an effective immune response and its therapeutic potential. D. nodosus serogroup B (JKS-07B strain) was grown in a modified TAS broth and a whole cell killed vaccine was prepared using 1.5 × 109 cells per dose, along with the oil adjuvant Montanide ISA 61 VG. The vaccine trial was conducted in sheep and two doses of the vaccine were given subcutaneously with a 30 days interval between the doses. The serum antibody titers in the vaccinated animals were measured at 0, 30, 60, 90, 120, and 150 days post-vaccination using the microplate agglutination test. Protective antibody titers (≥ 3000) were achieved by the 30th day following the primary vaccination in all animals, reaching their peak at the 60th day. The protective level of antibody titers was maintained up to 120 days following the primary vaccination. The vaccine also demonstrated a therapeutic effect in animals that were clinically affected. Animals with a lesion score of 2 took 18-21 days for recovery, while those with a lesion score of 3-4 took 40-47 days to recover from lameness.

Keywords

Dichelobacter nodosus, Antibody Titer, Montanide ISA 61 VG, Vaccine, Therapeutic Effect

Article Metrics

Article View: 134

Share This Article

© The Author(s) 2025. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.